CytoDyn (CYDY) Common Equity (2011 - 2026)
CytoDyn's (CYDY) quarterly Common Equity came in at -$104.3 million in Q1 2026, down 12.16% YoY from -$118.7 million in Q1 2025, and up 12.91% on a QoQ basis from -$119.7 million in Q4 2025.
CytoDyn (CYDY) Common Equity (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Common Equity data on file, last reported at -$104.3 million in Q1 2026.
- Quarterly Common Equity fell 12.16% year-over-year to -$104.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$104.3 million (down 12.16% YoY) and the FY2025 annual result came in at -$96.0 million, up 17.74% from the prior year.
- Common Equity grew to -$104.3 million in Q1 2026, from -$119.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$22.5 million in Q1 2022 to a low of -$119.7 million in Q4 2025.
- A 5-year average of -$99.9 million and a median of -$104.3 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 813.43% — and 2024, when it rose 27.1%.
- Tracing CYDY's Common Equity over 5 years: stood at -$116.0 million in 2022, then increased by 1.37% to -$114.4 million in 2023, then gained by 21.85% to -$89.4 million in 2024, then slumped by 33.96% to -$119.7 million in 2025, then advanced by 12.91% to -$104.3 million in 2026.
- The last three Common Equity figures came in at -$104.3 million (Q1 2026), -$119.7 million (Q4 2025), and -$99.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | -104.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -104.29 Mn |
| Nov 30, 2025 | -119.75 Mn |
| Aug 31, 2025 | -99.50 Mn |
| May 31, 2025 | -96.04 Mn |
| Feb 28, 2025 | -92.98 Mn |
| Nov 30, 2024 | -89.39 Mn |
| Aug 31, 2024 | -85.21 Mn |
| May 31, 2024 | -116.76 Mn |
| Feb 29, 2024 | -119.38 Mn |
| Nov 30, 2023 | -114.38 Mn |
| Aug 31, 2023 | -116.89 Mn |
| May 31, 2023 | -109.50 Mn |
| Feb 28, 2023 | -107.01 Mn |
| Nov 30, 2022 | -115.97 Mn |
| Aug 31, 2022 | -94.31 Mn |
| May 31, 2022 | -94.40 Mn |
| Feb 28, 2022 | -22.46 Mn |
| Nov 30, 2021 | -12.70 Mn |
| Aug 31, 2021 | -25.19 Mn |
| May 31, 2021 | -21.02 Mn |